In Sandoz's challenge to a once-weekly semaglutide patent, the Milan court claimed power to rule on validity even if Novo withdraws the patent text at the EPO.
Recap by typeshit. Full story at JUVE Patent.
The peptide item sits among gene therapy, Neuralink and Medicare news. The Alliance for Safe Biologic Medicines has asked HHS to pause the policy, citing FDA scientists.
Maria David Patten alleges Novo hid NAION risks; her case joins the federal MDL before Judge Karen Marston in Pennsylvania, where bellwether trials are expected.
HHS now lets pharmacies compound BPC-157, TB-500 and four others, but BoxingInsider notes all six remain on WADA's banned list for licensed boxers.
Politico looks at the warning signs around Health Secretary Kennedy's move to let six peptides that lack FDA approval reach the US market.
Rosario in Paris says the team's four AI-designed peptides looked right on paper but none reached the binding affinity they wanted, ending work begun in February.
A general overview of tirzepatide, an injectable that acts on two hormone pathways tied to blood sugar control and appetite.
Loading…